leukemia

[TG Therapeutics, Inc.] TG Therapeutics, Inc. announced the US FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date to June 25, 2022 for the Biologics License Application (BLA) and supplemental New Drug Application (sNDA) for ublituximab in combination with UKONIQ®as a treatment for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

[Cancer Immunology Research] Researchers tested the in vitro effect of different natural killer (NK)-cell engagers, which triggered either NKp46 or NKp30 together with CD16A, and targeted either CD19 or CD20 to induce killing of pediatric B cell precursor acute lymphoblastic leukemia.

[Nature Communications] Investigators showed that the adipocyte secretome upregulated the surface expression of Galectin-9 on human B-acute lymphoblastic leukemia cells which promoted chemoresistance.

[Oncogene] The authors used MLL-AF9-induced AML mouse models with interferon regulatory factor 7 (IRF7) knockout or overexpression and xenograft mouse models to explore the intrinsic effects of IRF7 in AML.

[Scientific Reports] The authors investigated the relationship amongst PTEN deletion, L-asparaginase sensitivity and glucose metabolism in T cell acute lymphoblastic leukemia cells.

[Nature Medicine] Through integrative molecular profiling of HSCs and progenitor cells in large patient cohorts, scientists found that myelodysplastic syndromes HSCs in two distinct differentiation states were maintained throughout the clinical course of the disease.